Mid cap News

Trump Media added that the shares of Truth Social would be distributed to its shareholders of record prior to the closing of the merger with TAE.

The week saw Joby beat Wall Street expectations for fourth-quarter revenue and reported a smaller-than-expected loss as production ramped up, pushing shares up.

The board authorized a new $50 million share repurchase program running through March 2027.

Novavax said it is pivoting toward a partnership-led model, including a licensing deal with Pfizer for its Matrix-M technology.

The company said that its material costs pushed out into the first quarter, delaying its path to profitability into 2026.

Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121.

Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday.

As the company focuses on growing its user base, Duolingo expects to have an impact in the short term, mainly on its profitability.

U.S. stock futures moved lower late Thursday as Nvidia’s 5.5% post-earnings drop weighed on semiconductor stocks.

Investor concern regarding growth continues to swirl as the company reported another annual loss and a revenue miss for the fourth quarter.

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Despite production adjustments, wait times have shortened, and ES8 remains a key profit driver, accounting for about 65% of December 2025 deliveries.

An algorithm change at an ad partner has impacted Oddity’s results, with the company now expecting about 30% fall in revenues for the first-quarter.

Earlier in the year, investors cheered SMR stock based on DOE’s $2.7 billion commitment to strengthen the uranium supply chain.

Koyfin analysts expect revenue to grow nearly 28% from the last quarter and forecast losses to narrow significantly.

Crypto-linked equities jumped on Wednesday amid Bitcoin’s rally to $69,000 but pared gains as BTC’s price came back down.

The company expects 2026 revenue in a range of $225 million to $245 million, with a midpoint of $235 million.

Heading into earnings, data shows that Celsius is gaining market share and competing with traditional soda brands like PepsiCo and Coca-Cola as more people lean into energy and lifestyle drinks.

The filing comes ahead of ImmunityBio’s participation in the ASCO Genitourinary Cancers Symposium.

Investors are optimistic about Joby’s growth prospects as FAA certification ramps up and the company prepares to fly its first passengers this year.

Sezzle’s revenue growth has soared, mainly driven by higher consumer engagement during the peak holiday season.

A new Cohort 8 study aims to reopen the non-walking patient market with data expected by the end of 2026.

ENVX stock is heading to snap a two-day winning streak as investors look for material growth mainly in its smartphone segment.

Investors assessed Nvidia’s earnings and China commentary alongside broader macro risks.

The San Francisco-based AI startup announced 10 new capabilities for enterprise customers to use its technology across functions such as coding, cybersecurity, human resources, and investment banking, among others.

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Zimbabwean Mines Minister Polite Kambamura said that the export ban is effective immediately until further notice.

First Solar’s full-year revenue came below Wall Street expectations and a quarterly profit miss has raised investor concerns regarding cost pressure due to tariffs.

Stocktwits data showed retail message volume around WULF’s stock jumped more than 270% over the past day, with sentiment shifting from ‘bearish’ to ‘bullish’ territory.

Joby Aviation stock gained enormously in 2025 but has tumbled since the beginning of the year on plans to raise capital in January.

The company also plans to unveil its new flagship ES9 SUV around April 10, with pricing expected in late May and deliveries starting June 1.

After the company’s stock rallied in January following Trump’s comments on lowering mortgage rates, investors have grown cautious about Rocket Companies' growth prospects amid AI disruption fears.

The company guided for $900 million to $1 billion in 2026 revenue.

Zeta’s AI-powered growth continues to keep investors happy, as news of an AI disruption that could negatively impact them had put them on edge.

Strong guidance and surging demand for high-protein, healthy meals lift Cava — but margin pressure and value-conscious consumers keep the battle tight.

Investors will also focus on Nvidia’s earnings, amid closer scrutiny of large-cap technology valuations and rising concerns over hyperscalers’ capital spending on AI.

The revision brought full-year output just below the roughly 18,000-unit guidance Lucid had set after cutting its target twice last year.

Traders debated whether Trump could reference cancer priorities or FDA reform, with some betting a mention could spark another leg higher for IBRX.

Ethereum co-founder Vitalik Buterin has sold more than 10,0000 ETH tokens in February after pledging to fund open-source projects.

Institutional support remains strong in February, with 134 investors increasing positions and 61 initiating new stakes.

After an 8% selloff tied to AI disruption fears, ZETA investors are betting Zeta can prove its artificial intelligence strategy is working in its favor.

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

ImmunityBio outlined a three-year plan to position Anktiva as a backbone immunotherapy, advancing more than 30 trials across 10 tumor types.

Traders are now looking ahead to a key Anthropic event on Tuesday, where new product announcements and demonstrations of Claude’s latest features are expected.

Kratos’ earnings call provided insights into the contracts it has received for 2026, noting it is slated for margin expansion this year.

The company reiterated its longer-term targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.

Capricor is approaching a regulatory filing timeline and earnings, while Sarepta heads into results under legal and safety pressure.

Sky News reported expectations of “record profits” in the upcoming results.

The chairman pointed to upcoming updates on IL-15’s long-studied role in cancer immunotherapy.

Lemonade’s stock has declined over the last few days due to its core profit growth target being, in hindsight, missed, even as the company delivers on revenue.